OPKO HEALTH, INC.
OPKNext catalyst
CTAP101
Chronic Kidney Disease
Get an email about OPK's next catalysts
Track OPKO HEALTH (OPK) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
CTAP101 Phase 2 Est. Readout
Estimated primary completion for CTAP101 trial (NCT07494045) in CKD Stage 3. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
WebsiteCalcitriol
Chronic Kidney Disease
Genotropin
Growth Hormone Deficiency
CTAP101 Capsules
Chronic Kidney Disease
MOD-4023
Pediatric Growth Hormone Deficiency
Cohort 1 CTAP101
Chronic Kidney Disease
Somatropin
Pediatric Growth Hormone Deficiency
CTAP101
Chronic Kidney Disease
Doxercalciferol
Chronic Kidney Disease
Cohort 2 CTAP101
Chronic Kidney Disease
CTA018 cream
Psoriasis
Rayaldee
COVID-19
OPK-88006
MASH
LY2944876
Diabetes Mellitus, Type 2
MDX2003
Lymphoma
Exenatide extended-release
Diabetes Mellitus, Type 2
TT223 with Metformin and/or TZD
Diabetes Mellitus, Type 2
MDX2004
Advanced Tumors
OPK-88003
Type 2 Diabetes Mellitus
ELND005 (scyllo-inositol)
Alzheimer's Disease
ELND005
Alzheimer's Disease
bevasiranib
Diabetic Macular Edema
MDX2001
Biliary Tract Cancer
CTA018 Injection
Chronic Kidney Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Calcitriol | Phase 3 | Chronic Kidney Disease | - | - |
Genotropin | Phase 3 | Growth Hormone Deficiency | - | - |
CTAP101 Capsules | Phase 3 | Chronic Kidney Disease | - | - |
MOD-4023 | Phase 3 | Pediatric Growth Hormone Deficiency | - | - |
Cohort 1 CTAP101 | Phase 3 | Chronic Kidney Disease | - | - |
Somatropin | Phase 3 | Pediatric Growth Hormone Deficiency | - | - |
CTAP101 | Phase 3 | Chronic Kidney Disease | - | - |
Doxercalciferol | Phase 3 | Chronic Kidney Disease | - | - |
Cohort 2 CTAP101 | Phase 3 | Chronic Kidney Disease | - | - |
CTA018 cream | Phase 2 | Psoriasis | - | - |
Rayaldee | Phase 2 | COVID-19 | - | - |
OPK-88006 | Phase 2 | MASH | - | - |
LY2944876 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
MDX2003 | Phase 2 | Lymphoma | - | - |
Exenatide extended-release | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
TT223 with Metformin and/or TZD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
MDX2004 | Phase 2 | Advanced Tumors | - | - |
OPK-88003 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ELND005 (scyllo-inositol) | Phase 2 | Alzheimer's Disease | - | - |
ELND005 | Phase 2 | Alzheimer's Disease | - | - |
bevasiranib | Phase 2 | Diabetic Macular Edema | - | - |
MDX2001 | Phase 2 | Biliary Tract Cancer | - | - |
CTA018 Injection | Phase 2 | Chronic Kidney Disease | - | - |
Frequently asked questions
What is in OPKO HEALTH, INC.'s drug pipeline?→
CatalystAlert tracks 23 drug candidates in OPKO HEALTH, INC.'s (OPK) pipeline across Phase 3, Phase 2. Its lead program is CTAP101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is OPKO HEALTH, INC.'s next FDA catalyst?→
OPKO HEALTH, INC.'s (OPK) next tracked catalyst is a Phase 2 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OPK biotech catalysts?→
Add OPK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OPKO HEALTH, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.